Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.